This is a preview of subscription content, log in via an institution to check access.
Reference
Chhatwal J, et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value in Health 16: 973-86, No. 6, 1 Sep 2013. Available from: URL: http://dx.doi.org/10.1016/j.jval.2013.07.006
Additional information
* An international, randomised, multicentre, double-blind study comparing boceprevir added to PR with PR alone.
** A trial comparing telaprevir plus PR with PR alone.
† incremental cost-effectiveness ratios
Rights and permissions
About this article
Cite this article
Boceprevir cost effective in hepatitis C infection. PharmacoEcon Outcomes News 688, 7 (2013). https://doi.org/10.1007/s40274-013-0758-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0758-y